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Neurodegenerative diseases are one of the main causes of mental and physical
disabilities. Neurodegeneration has been estimated to begin many years before the first
clinical symptoms manifest, and even a prompt diagnosis at this stage provides very little
advantage for a more effective treatment as the currently available pharmacotherapies
are based on disease symptomatology. The etiology of the majority of neurodegenerative
diseases remains unknown, and even for those diseases caused by identified genetic
mutations, the direct pathways from gene alteration to final cell death have not yet been
fully elucidated. Advancements in genetic engineering have provided many transgenic
mice that are used as an alternative to pharmacological models of neurodegenerative
diseases. Surprisingly, even the models reiterating the same causative mutations do not
fully recapitulate the inevitable neuronal loss, and some fail to even show phenotypic
alterations, which suggests the possible existence of compensatory mechanisms.
A better evaluation of these mechanisms may not only help us to explain why
neurodegenerative diseases are mostly late-onset disorders in humans but may also
provide new markers and targets for novel strategies designed to extend neuronal
function and survival. The aim of this mini-review is to draw attention to this under-
explored field in which investigations may reasonably contribute to unveiling hidden
reserves in the organism.
Keywords: neurodegeneration, compensation, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease,
transgenic mice, genetic models
Introduction
The prevalence of neurodegenerative diseases, currently one of the main causes of mental
and physical disabilities, has consistently risen because of the progressive aging of the
worldwide population and is especially affecting highly developed societies. Examples of the
more well-known neurodegenerative diseases include Alzheimer’s disease (AD), Parkinson’s
disease (PD) and Huntington’s disease (HD), but a myriad of other rare neurodegenerative
disorders exist, e.g., Pick’s disease, Creutzfeldt-Jakob disease (CJD), progressive supranuclear
palsy (PSP), and amyotrophic lateral sclerosis (ALS). However, regardless of the nature
of the disease, neural loss in the majority of the cases is estimated to usually begin
10--20 years before the first clinical symptoms appear and even a prompt diagnosis at
this stage provides very little advantage for further effective treatment. Moreover, most of
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the cases have a sporadic occurrence, and even for those in
which the genetic factors have been determined, the distinct
molecular pathways leading to final cell death remain unclear.
Therefore, the currently available pharmacotherapies are based
on disease symptomatology and, apart from alleviating the
typical symptoms, they do not restore neuronal function or
prevent neuronal loss.
Most of the classic animal models for neurodegeneration are
based on applying neurotoxins---an effective strategy for studying
phenotype but this generates immediate neuronal death, which
severely limits the opportunity to observe the molecular changes
associated with the authentic, slow neurodegenerative process.
Thus, the statement, ‘‘the lack of a good animal model is
frustrating in efforts to curb disease progression’’ (Beal, 2010)
appears to still be valid, despite the progress in research focused
on neurodegeneration.
Why Can We Not Fully Replicate Genetic
Diseases in Transgenic Animals?
Advancements in genetic engineering over the last two decades
have provided many transgenic mice that have been exploited
as alternative, genetic models for various neurodegenerative
diseases. These transgenic mice were created by either precisely
targeting the same causative genes involved in the human
disorders (e.g., HD, some rare familiar forms of PD and AD)
or the genes controlling the subcellular changes and processes
affected in the diverse neuropathological conditions, such as
oxidative stress, rRNA synthesis, inflammation or mitochondrial
dysfunction (Schwab et al., 2010; Parlato and Kreiner, 2013;
Pickrell et al., 2013; Ribeiro et al., 2013). Surprisingly, many of
these models do not fully recapitulate the inevitable neuronal loss
(or at least not to the expected extent), supporting the proposal
that different genetic, cellular and environmental factors may
contribute to the ultimate cell death. Some transgenic mice
fail to even demonstrate the phenotypic alterations associated
with the modeled diseases, providing further evidence that
humans and primates can be more vulnerable than rodents to
the same triggers inducing neurodegeneration, a phenomenon
also observed in pharmacological models (Przedborski et al.,
2001).
In particular, extensively studied transgenic AD models,
such as mice overexpressing β-amyloid precursor protein
(APP, disputably but generally accepted contributing factor
to AD), PS1 and PS2 (expressing mutated presenilin-
1 and presenilin-2, respectively), APP/PS1 (harboring
human transgenes for both APP and PS1 together) and
Tg2676 (overexpressing a mutant form of APP), do not
demonstrate the expected loss of neural cells (Duff et al.,
1996; Oyama et al., 1998; Elder et al., 2010). Conversely,
there are examples of models in which cognitive functions
remain intact despite overexpression of APP (Masliah
et al., 2001). Moreover, the so called ‘‘tau pathology’’
---formation of neurofibrillary tangles (NFT) due to hyper-
phosphorylation of a microtubule-associated protein, which
is another characteristic feature of AD---was not observed
in most of the APP overexpressing models (Ribeiro et al.,
2013). Another approach of creating AD transgenic mice
models was related to tau proteins. Hyperphosphorylation of
microtubule-associated protein tau (MAPT) can result in the
self-assembly of NFT being involved in the pathogenesis of AD.
The first transgenic model designed upon targeting tau protein
did come out with any visible neurological phenotype (Gotz
et al., 1995). Further attempts revealed only minor motoric
impairments and tau protein accumulation (mostly in brain
and spinal cord), however classic NFT were not observed or
narrowed only to certain neural tissues (Eriksen and Janus,
2007; Wiedlocha et al., 2012). On the other hand, in the Htau
mice characterized by expressing six isoforms of human tau
without containing any mouse tau protein, the development
of NFT was not correlated to the direct phenotype of the
mutation and extensive neuronal loss in aged mice (Andorfer
et al., 2003, 2005) indicating that the mechanism of Tau-
mediated neuronal cell death remains elusive (Andorfer et al.,
2005).
These discrepancies between the expected and observed
phenotypes were particularly surprising in transgenic models
created by directly targeting the identified causative genes.
In the case of PD, there are currently recognized up to 20
genetic loci that have been described and implicated in the
pathogenesis of PD, in which the mutations contribute to the
familial form of PD (Scholz et al., 2012). However, none of
the rodent models created by targeting these genes demonstrate
profound neurodegeneration of dopaminergic cells, including
the dominant mutation in leucine-rich repeat kinase 2 (LRRK2),
the most widespread mutation among humans (Chesselet and
Richter, 2011; Bezard et al., 2013).
Perhaps the most disappointing results have come from the
classic models of HD. Huntington’s disease is a progressive
autosomal dominant inherited neurodegenerative disease that
is characterized by uncontrolled movements (chorea) together
with emotional and cognitive symptoms and inevitably leads
to death within approximately 20 years. The cause of HD
has been known since 1993, when it was identified as
a polyglutamine (polyQ) expansion of a stretch of CAG
repeats in the amino-terminal region of the huntingtin (HTT)
protein (MacDonald, 1993). Therefore, one would expect that
an accurate replication of the genetic malfunction directly
responsible for HD in humans should result in exactly the
same phenotype in mice. In fact, knock-in HD mice with
expanded polyQ tracts do not differ from their control littermates
in life span or body weight, demonstrating only mild motor
deficits and very moderate cell loss (Lin et al., 2001). Moreover,
this resistance to the mutation is emphasized by the fact
that these mouse models harbor a considerably larger CAG
expansion than is necessary to induce the human form of
HD. Thus, it may be concluded that mutant HTT (mHTT)
appears to be more toxic to primates than to rodent models.
Paradoxically, despite knowing the precise mutation responsible
for HD for more than 20 years, the most studied transgenic
animal model of HD is the R6/2 mouse, which was created
by expressing the amino-terminal region of HTT, thus not
accurately representing the cause of the disease (Li et al.,
2005).
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The aforementioned observations provide clues to the
potential compensatory mechanisms that protect neurons
from death in the evaluated genetic models, which may
help us to understand the preclinical deficits observed in
neurodegenerative diseases and provide better insight into the
pathogenic mechanisms underlying the initial, symptomless
phase of their onset. There are several candidate pathways
and molecules whose activation can be considered as an
effect of the compensatory processes evoked in response to
the introduced mutations. The limited content of this mini-
review will not allow for a discussion of all the possible
dilemmas but will concentrate on a selected intriguing examples
based on the very recent literature, listed in alphabetical
order.
Autophagy
Autophagy is a self-degradative process that removes
unnecessary or dysfunctional cellular components through
the actions of lysosomes and is important for balancing
sources of energy at critical times during development, and
in response to any type of cellular stress. It is generally
considered a pro-survival mechanism (Glick et al., 2010). Thus,
autophagy may be an essential factor that maintains neuronal
homeostasis, and its impairment has been implicated in the
development of neurodegenerative pathologies (Bakhoum
et al., 2014). Additionally, it has also been proposed that
the autophagy-lysosomal activities may play a pivotal role
in neurodegenerative diseases by removing damaged or
dysfunctional proteins and organelles that are a cause of
oxidative stress, such that autophagy may be considered
an antioxidant system (Giordano et al., 2013). Induction
of autophagy has also been reported to be associated with
rescue of the tau pathology, which suggests that formation
of autophagosomes may be considered a compensatory
mechanism rather than a trigger for neurodegeneration
(Bakhoum et al., 2014). Our recent study, exploiting the new
model of HD-like neurodegeneration based on the selective
removal of transcription factor TIF-IA from medial spiny
neurons (MSN), revealed that the transient upregulation of
phosphatase and tensin homolog deleted on chromosome 10
(PTEN) kinase, a tumor suppressor that inhibits mammalian
targeting of rapamycin signaling and induces autophagy,




Alterations in the ERK pathway have been reported in some
neurodegenerative diseases, accompanied by an increase in the
protein levels of ribosomal S6 kinases (RSK) in several models
of HD (Xifro et al., 2011). RSK are involved in cell growth
and survival, and are regulated by phosphorylation controlled
by mitogen-activated protein (MAP) kinases, including ERK
(Chen et al., 1992). Pharmacological inhibition of RSK, as well
as knock-down and overexpression experiments, have indicated
that RSK activity exerts a protective effect and may act as a
compensatory mechanism with the capacity to prevent cell death
in HD (Xifro et al., 2011). Another study reported a role of
the regulator of G-protein signaling 2 (RGS2) in controlling
the compensatory response in the striatal neurons of HD
models, suggesting that RGS2 inhibition may be considered an
innovative target for neuroprotection (Seredenina et al., 2011).
An investigation of the possible mechanism underlying RGS2-
mediated neuroprotection revealed that RGS2 downregulation
enhanced activation of the ERK pathway (Seredenina et al.,
2011).
Glycolysis
Glycolysis, the well-known metabolic pathway of glucose
degradation resulting in formation of the high-energy
compounds ATP and NADH, may also be involved in
a compensatory response in neurodegenerative diseases.
Glycolysis has been shown to compensate for mitochondrial
dysfunction at the motor terminals of SOD1 transgenic mice
(most widely used animal model of ALS), and this mechanism
may help to support metabolism in the presence of dysfunctional
mitochondria (Carrasco et al., 2012).
Metalloproteases
Metalloproteases are a group of enzymes that contain a catalytic
metal ion at their active site and assist in the hydrolysis
of peptides, which ultimately leads to protein degradation.
Metalloproteases are important in many developmental
processes, including cell proliferation, differentiation
and migration (Chang and Werb, 2001). Endogenous
metalloproteases have been proposed to regulate mitochondrial
activity in degenerating neurons, and their activation may be
regarded as an adaptive and compensatory response to stressful
stimuli to protect mitochondrial function (de Oca Balderas
et al., 2013). Specifically, it has been shown that metalloprotease
inhibition stimulates mitochondrial activity impairment induced
by 3-nitropropionic acid (3-NP, striatal cell neurotoxin), and
metalloproteases may be involved in the cellular reorganization
induced by 3-NP (de Oca Balderas et al., 2013).
Neurotrophins and Neurogenesis
Neurotrophins are a family of proteins that stimulate the
development, differentiation and survival of neurons and are
thus natural candidates for self-defense in case of neuronal
loss. Neurotrophins can help to stimulate and control de
novo neurogenesis. However it has been debated whether this
phenomenon has any functional relevance, neurogenesis in the
adult brain has also been proposed as a possible compensatory
mechanism activated in response to environmental and genetic
cues (Pierce and Xu, 2010).
One of the most studied and well-known triggers of
neurogenesis is brain-derived neurotrophic factor (BDNF). It has
been suggested that an increase in BDNF expression may reflect
a compensatory mechanism against early neurodegeneration
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(Faria et al., 2014). Specifically, increased BDNF levels have
been reported in early stages of AD; these levels decrease over
the course of the disease and are inversely correlated with
dementia (Laske et al., 2006). It has also been reported that
serum levels of BDNF are significantly lower in PD patients and
correlate with the advancement of motor impairment (Scalzo
et al., 2010). Several studies have shown that a loss of BDNF
protein in the brains of HD patients may contribute to the
clinical manifestation of the disease (Zuccato and Cattaneo,
2014).
Turning back to animal models, it was recently shown that
neurotrophin treatments used on transgenic mouse models of
AD lead to a reduction in Aβ generation that was mostly
dependent on the BDNF-mediated decrease in glycogen synthase
kinase-3-β (GSK3β) activity, emphasizing the potential of
neurotrophins as targets for disease modifying therapy (Kazim
et al., 2014). Experiments performed on mice hypomorphic
for TrkB tyrosine kinase receptor (mainly activated by BDNF)
have revealed a profound loss of dopaminergic neurons in
the region of the substantia nigra (SN) together with elevated
levels of dopamine in the striatum and yet no alteration in
the turnover of this neurotransmitter (Zaman et al., 2004).
These findings were associated with increased BDNF levels in
the striatum but not the SN, suggesting the existence of a
putative compensatory mechanism that follows dopaminergic
cell loss in the SN (Zaman et al., 2004). An interesting
recent study by the Minichiello group in a novel genetic
mouse model showed that the selective removal of BDNF from
enkephalinergic striatal neurons results in spontaneous and
drug-induced hyperlocomotion associated with dopamine D2
receptor-dependent increased striatal protein kinase C (PKC)
and MAP kinase activation, a mechanism that may have impact
on striatal neuron vulnerability in the early-stage of HD (Besusso
et al., 2013).
Noradrenaline
Noradrenaline (NA) is one of the most important
neurotransmitter in the brain and the projections of
noradrenergic neurons originating in the locus ceruleus
penetrate virtually all brain structures. Degeneration of
noradrenergic neurons is observed both in PD and AD to
even greater extent and exacerbate the loss of dopaminergic
and cholinergic neurons, respectively (Zarow et al., 2003).
Experimental data indicate the important involvement of
NA associated with PD brain damage i.e., the loss of NA in
PD can worsen the dopamine nigrostriatal damage and, in
opposite---an enhanced level of NA may have a neuroprotective
effect (Srinivasan and Schmidt, 2003; Rommelfanger et al.,
2004). These data prompt a statement that NA may
serve as a compensatory mechanism in PD dopaminergic
neurodegeneration (Rommelfanger and Weinshenker, 2007).
In a genetic mouse model of PD based on damaged
mitochondrial DNA in dopaminergic neurons it was proven
that NA and serotonin were increased after the dopaminergic
cell loss (Pickrell et al., 2011). Recently, it has been shown that
mirtazapine, an noradrenergic and serotonergic antidepressant
drug, has a therapeutic potency in a classic pharmacological
model of PD, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) treated mice (Kadoguchi et al., 2014).
The activation of NA in human neuronal cultures and
rat primary hippocampal neurons protects against neuronal
amyloid toxicity by stimulating neurotrophic pathways (Counts
and Mufson, 2010). In rats with the lesion of medial septum
cholinergic neurons, sprouting of noradrenergic sympathetic
fibers triggered by neurotrophins was noted, contributing to
cholinergic reinnervation what experimentally reiterated the
clinical implications of sprouting as an innate compensatory
mechanism (Nelson et al., 2014).
PKCδ (Protein Kinase Cδ)
PKC belongs to the group of enzymes that regulate the
function of other proteins at the intracellular level and thus
influence important cellular functions, including proliferation
and apoptosis (Griner and Kazanietz, 2007). A balance
between cell survival and apoptosis is crucial for avoiding
neurodegeneration, and alterations in PKC activity have been
associated with various neurodegenerative disorders, including
AD, PD and HD. Recently, it was shown that an increase in the
degradation of the PKCδ isoform is related to the compensatory
pro-survival mechanism activated in response tomHTT-induced
toxicity and is responsible for a delay in neuronal loss in HD (Rué
et al., 2014). Consistent with this observation, overexpression of
the PKCδ isoform in vitro enhances the negative effects of mHTT
(Rué et al., 2014).
Conclusions
Lack of a desired broad-spectrum phenotype and content
validity of some transgenic mice used as models of various
neurodegenerative diseases is often regarded as a caveat of further
practical exploiting of these models and prompts researchers
pursuing for alternative models, neglecting the ones which did
not fully meet their expectations. However, this failure can
be turned into a feature considering that behind the simple
resistance to the introduced mutation, there may be a huge
variety of compensatory processes delaying or attenuating the
expected phenotype in the rodent genetic models. A better
evaluation and understanding of these mechanisms may help us
to not only explain why neurodegenerative diseases are mostly
late-onset disorders in humans but may also provide new disease
markers and targets for novel strategies designed to extend
neuronal function and survival. Such attempts are apparently
rare. Surprisingly, only very few studies describing the observed
phenotypes of different genetic models of neurodegenerative
diseases have focused on this problem, and these mechanisms
were barely investigated in these papers.
The aim of this mini-review is to focus attention on
this under-explored field in which investigations may
reasonably contribute to unveiling hidden reserves within
the organism, particularly important in a preclinical stages
of neurodegenerative diseases. Perhaps this is the time to
reevaluate the initial descriptive characteristics of the transgenic
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mice created upon targeting the same causative genes as in
human neurodegenerative diseases, and pursue the potential
compensatory mechanisms underlying introduced mutations
that do not result in the expected phenotype.
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